Eli Lilly to Invest over US$3.5 Billion in Pennsylvania, USA
Introduction:
Eli Lilly and Company has announced plans to invest more than US$3.5 billion in a new injectable medicine and device manufacturing facility in Lehigh Valley, Pennsylvania, USA.
Features:
The development involves the construction of an injectable medicine and device manufacturing facility to support the production of therapies for weight loss and related conditions. It will also accommodate next-generation treatment candidates currently under development.
Production processes will include advanced injectable formulation and device assembly activities, with a focus on enabling large-scale and consistent supply.
The site will incorporate digital technologies such as artificial intelligence and data analytics to support manufacturing operations. It will form part of a broader pharmaceutical manufacturing network in the United States and was selected based on its proximity to technical infrastructure, utilities, and research institutions.
The facility expected to become operational in 2031.
Specifications:
| Name | Eli Lilly |
| Type | New Construction |
| Budget | US$3.5 Billion |
| Year | 2031 |
